Severe thrombocytopenia and alveolar hemorrhage represent two types of bleeding tendency during tirofiban treatment: Case report and literature review

International Journal of Hematology

Volumn 96, Issue 3, 2012, Pages 370-375

  Elcioglu, Omer Celal ^a   Ozkok, Abdullah ^a   Akpınar, Timur Selcuk ^a   Tufan, Fatih ^a   Sezer, Murat ^a   Umman, Sabahattin ^a   Besısık, Sevgi Kalayoglu ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Acute coronary syndrome; Alveolar hemorrhage; Thrombocytopenia; Tirofiban

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; EDETIC ACID; ENALAPRIL; FUROSEMIDE; GLYCERYL TRINITRATE; HEMOGLOBIN; HEPARIN; METOPROLOL; TIROFIBAN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLEEDING TENDENCY; CASE REPORT; CONTINUOUS INFUSION; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; DRUG INDUCED DISEASE; DRUG USE; DRUG WITHDRAWAL; DYSPNEA; FIBEROPTIC BRONCHOSCOPY; FOLLOW UP; HEART VENTRICLE FIBRILLATION; HEMOGLOBIN BLOOD LEVEL; HEMOPTYSIS; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE UNIT; LEFT CORONARY ARTERY; LOW DRUG DOSE; LUNG EDEMA; LUNG HEMORRHAGE; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OXYGEN SATURATION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; RESTENOSIS; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THORAX PAIN; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

EID: 84866992699     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-012-1133-7     Document Type: Article

References (39)

1. Karvouni E, Katritsis DG, Ioannidis J. Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions. J Am Coll Cardiol. 2003;41:26-32.
2. Huxtable LM, Tafreshi MJ, Rakkar ANS. Frequency and management of thrombocytopenia with the glycoprotein IIb/IIIa receptor antagonists. J Am Coll Cardiol. 2006;97:426-9.
3. Labinaz M, Ho C, Banerjee S, Martin J, Chen S, Mensinkai S. Meta-analysis of clinical efficacy and bleeding risk with intravenous glycoprotein IIb/IIIa antagonists for percutaneous coronary intervention. Can J Cardiol. 2007;23(12):963-70.
4. Kondo K, Umemura K. Clinical pharmacokinetics of tirofiban, a nonpeptide glycoprotein IIb/IIIa receptor antagonist: comparison with the monoclonal antibody abciximab. Clin Pharmacokinet. 2002;41:187-95.
5. The RESTORE Investigators. Effects of platelet glycoprotein IIb/ IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation. 1997;96:1445-53.
6. Neumann FJ, Blasini R, Schmitt C, Alt E, Dirschinger J, Gawaz M, Kastrati A, Schömig A. Effects of platelet glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation. 1998;98: 2695-701.
7. The PRISM-PLUS investigators. Glycoprotein IIb/IIIa receptor blockade improves outcomes in diabetic patients presenting with unstable angina/Non-ST-elevation myocardial infarction. Results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patient Limited by Unstable Signs and Symptoms (PRISM-PLUS) study. Circulation. 2000;102:2466-72.
8. Lee DP, Herity NA, Hiatt BL, Fearon WF, Rezaee M, Carter AJ, Huston M, Schreiber D, DiBatttiste PM, Yeung AC. Adjunctive platelet glycoprotein IIb/IIIa receptor inhibition with tirofiban before primary angioplasty improves angiographic outcomes: results of the TIrofiban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) Pilot Trial. Circulation. 2003;107:1497-501.
9. Topol EJ, Moliterno DJ, Herrmann HC, et al. for the TARGET investigators. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med. 2001;344:1888-94.
10. Merlini PA, Rossi M, Menozzi A, Buratti S, Brennan DM, Moliterno DJ, Topol EJ, Ardissino D. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting. Circulation. 2004;109: 2203-6.
11. Ali A, Patil S, Grady KJ, Schreiber TL. Diffuse alveolar hemorrhage following administration of tirofiban or abciximab: a nemesis of platelet glycoprotein IIb/IIIa inhibitors. Catheter Cardiovasc Interv. 2000;49(2):181-4.
12. Patel S, Patel M, Din I, Reddy CVR, Kassotis J. Profound thrombocytopenia associated with tirofiban: case report and review of literature. Angiology. 2005;56:351-5.
13. Bugie DW, Wilker PR, Wuitschick ED, Curtis BR, Malik M, Levine S, Lind RN, Pereira J, Aster RH. Acute thrombocytopenia after the treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa. Blood. 2002;100:2071-6.
14. Demirkan B, Guray Y, Guray U, Korkmaz S. Differential diagnosis and management of acute profound thrombocytopenia by tirofiban: a case report. J Thromb Thrombolysis. 2006;22:77-8.
15. Mulot A, Moulin F, Fohlen-Walter A, Angioi M, Sghaier M, Carteaux JP, Lecompte T, de Maistre E. Practical approach to the diagnosis and management of thrombocytopenia associated with tirofiban treatment. Am J Hematol. 2004;77:67-71.
16. Eryonucu B, Tuncer M, Erkoc R. Repetitive profound thrombocytopenia after treatment with tirofiban: a case report. Cardiovasc Drugs Ther. 2004;18:503-5.
17. Dunkley S, Lindeman R, Evans S, Casten R, Jepson N. Evidence of platelet due to tirofiban-dependent platelet antibodies: double trouble. J Thromb Haemost. 2003;1(10):2248-50.
18. George JN, Aster NH. Drug-induced thrombocytopenia: pathogenesis, evaluation, and management. Hematol Am Soc Hematol Educ Program. 2009;1:153-8 (Review).
19. Aster RH, Bougie DW. Drug-induced immune thrombocytopenia. N Engl J Med. 2007;357:580-7.
20. Aster RH, Curtis BR, Bougie DW. Thrombocytopenia resulting from sensitivity to GPIIb-IIIa inhibitors. Semin Thromb Hemost. 2004;30(5):569-77. Review.
21. Billheimer JT, Dicker IB, Wynn R, Bradley JD, Cromley DA, Godonis HE, et al. Evidence that thrombocytopenia observed in humans treated with orally bioavailable glycoprotein IIb/IIIa antagonists is immune mediated. Blood. 2002;99(10):3540-6.
22. George JN, Raskob GE, Shah SR, Rizvi MA, Hamilton SA, Osbome S, Vondracek T. Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Intern Med. 1998;129(11):886-90.
23. .Andres E, Dali-Youcef N, Serraj K, Zimmer J. Recognition and management of drug-induced cytopenias: the example of idisyncratic drug-induced thrombocytopenia. Expert Opin Durg Saf. 2009;8(2):183-90.
24. Reese JA, Li X, Hauben M, Aster RH, Bougie DW, Curtis BR, George JN, Vesely SK. Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods. Blood. 2010;116(12):2127-33. Epub 2010 Jun 8.
25. Aster RH. Immune thrombocytopenia caused by glycoprotein IIb/ IIIa inhibitors. Chest. 2005;127(2 suppl):53S-9S.
26. Becker PS, Miller VT. Heparin-induced thrombocytopenia. Stroke. 1989;20(11):1449-59.
27. Clofent-Sanchez G, Harizi H, Nurden A, Coste P, Jais C, Nurden P. A case of profound and prolonged tirofiban-induced thrombocytopenia and its correction by intravenous immunoglobulin G. J Thromb Haemost. 2007;5(5):1068-70.
28. Bosco A, Kidson-Gerber G, Dunkley S. Delayed tirofibaninduced thrombocytopenia: two case reports. J Thromb Haemost. 2005;3(5):1109-10.
29. Said SM, Hahn J, Schleyer E, Müller M, Fiedler GM, Buerke M, Prondzinsky R. Glycoprotein IIb/IIIa receptor inhibitor-induced thrombocytopenia: diagnosis and treatment. Clin Res Cardiol. 2007;96(2):61-9.
30. Sakellariou D, Pastromas S, Koulouris S, Manolis AS. First report of tirofiban-induced anemia (found in combination with severe thrombocytopenia). Tex Heart Inst J. 2009;36(1):55-7.
31. Lin YL, Chen LL, Luo YK, Zheng XC, Li WW. Benefit of standard versus low-dose tirofiban for percutaneous coronary intervention in very elderly patients with high-risk acute coronary syndrome. Acta Pharmacol Sin. 2009;30(5):553-8.
32. Guo J, Xu M, Xi Y. Tirofiban-induced diffuse alveolar hemorrhage: after primary angioplasty. Tex Heart Inst J. 2012;39(1): 99-103.
33. Yilmaz MB, Akin Y, Biyikoglu SF, Guray U, Korkmaz S. Diffuse alveolar hemorrhage following administration of tirofiban in a patient with acute coronary syndrome: a fatal complication. Int J Cardiol. 2004;93(1):81-2.
34. Matsuno O, Okubo T, Hiroshige S, Takenaka R, Ono E, Ueno T, et al. Drug-induced lymphocyte stimulation test is not useful for the diagnosis of drug-induced pneumonia. Tohoku J Exp Med. 2007;212(1):49-53.
35. Saito M, Yagi M, Uno K, Takanaka K. Comparative study of the usefulness of the drug-induced lymphocyte stimulation test and the leukocyte migration test in drug allergies. Biol Pharm Bull. 2008;31(2):209-304.
36. Huynh T, Piazza N, DiBattiste PM, Snapinn SM, Wan Y, Pharand C, Theroux P. Analysis of bleeding complications associated with glycoprotein IIb/IIIa receptor blockade in patients with high-risk acute coronary syndromes: insights form the PRIM-PLUS study. Int J Cardiol. 2005;100:73-8.
37. Dasgupta H, Blankenship JC, Wood GC, Frey CM, Demko SL, Menapace FJ. Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis. Am Heart J. 2000;140:206-11.
38. Tuhta AG, Yesildaǧ O, Köprülü D. Tirofiban-associated acute thrombocytopenia. Acta Cardiol. 2006;61(5):577-9.
39. Rahman N, Jafary FH. Vanishing platelets: rapid and extreme tirofiban-induced thrombocytopenia after percutaneous coronary intervention for acute myocardial infarction. Tex Heart Inst J. 2010;37(1):109-12.